Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact.As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing roughly $4 billion in follow-on investment across 17 companies.View full story: https://www.biocentury.com/article/659476#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch00:00 - Introduction01:34 - Optimizing Translation07:42 - Training the Immune System16:33 - China’s Opportunity20:50 - Need for a Cancer Strategy24:40 - Enhancing Cancer Survivorship27:55 - Scientific Foundation Under Threat